Researchers at UCLA reported enhancer-targeted CRISPR activation that rescues haploinsufficiency phenotypes in human brain organoid models of autism, according to a Nature Neuroscience study described in reporting. Using dCas9-p300 without cutting DNA, the team focused eCRISPR-A on fetal-brain enhancers for CHD8 and SCN2A to avoid promoter overexpression risks. The approach sustained increased gene expression in mutant neurons and organoids and corrected multiple downstream phenotypes, including organoid growth and neuronal maturation markers in CHD8 models. In SCN2A mutant neurons, the therapy restored excitability toward wild-type levels. The work highlights a precision approach to dosing gene expression—an important design constraint for dosage-sensitive autism genes—and reinforces organoids as translational screening platforms for gene regulation strategies.
Get the Daily Brief